The Metabolic Advantage. Studied. Measured. Proven in Research.
Obesity research has entered a new era. Triple-receptor agonists and growth hormone fragments are reshaping how scientists model metabolic dysfunction. NexPep's Weight Management peptides put the most studied metabolic compounds directly in your research pipeline—at uncompromising purity.
3 Compounds Available
All in-stock · UK delivery
Nexora Pharma Retatrutide 30mg + Free BW
NXR-RETA-30MGNexora Pharma Retatrutide 30mg is a triple agonist peptide that activates GLP-1, GIP, and glucagon receptors. It enhances insulin secretion, increases energy expenditure, and reduces appetite, resulting in significant improvements in weight loss and metabolic regulation.
Nexora Pharma AOD-9604 5mg
NXR-AOD-9604-5MGNexora Pharma AOD-9604 5mg is a synthetic fragment of human growth hormone (hGH 176-191). Researched extensively for its role in lipid metabolism, fat-cell regulation, and metabolic research applications. This stable peptide demonstrates notable activity in preclinical models examining lipolysis stimulation and lipogenesis inhibition, without the broader systemic effects associated with full-length growth hormone. Lab verified 99%+ purity.
Nexora Pharma Tesamorelin 5mg
NXR-TESAMORELIN-5MGNexora Pharma Tesamorelin 5mg is a synthetic analog of growth hormone-releasing hormone (GHRH). Researched extensively for its role in stimulating endogenous growth hormone secretion and regulating visceral fat metabolism. This stabilized peptide demonstrates notable activity in preclinical and clinical models examining GH/IGF-1 axis modulation, lipid metabolism, and body composition research applications. Lab verified 99%+ purity.
The Science Behind Weight Management
Lipolysis Research
AOD-9604 is a 15-amino-acid fragment of the C-terminus of human growth hormone—studied specifically for its fat oxidation properties without anabolic interference.
Multi-Receptor Targeting
Retatrutide's GLP-1/GIP/glucagon triple-agonism is driving the most exciting metabolic syndrome research of the decade.
Precision Dosing Models
Formulated for in-vitro and in-vivo research applications requiring high-concentration, high-purity compounds.
Research Notes
Retatrutide (LY3437943) activates receptors for GLP-1, GIP, and glucagon—a mechanism that goes beyond current dual-agonist therapies. AOD-9604 (hGH 176-191) demonstrates lipolytic and antilipogenic activity in animal studies without detectable impact on insulin sensitivity.
Third-Party Tested
Every batch verified by independent HPLC and mass spectrometry before release.
≥99% Purity
Certificate of Analysis available on request for your batch. No compromises.
Research Use Only
Formulated exclusively for licensed researchers and institutions.
Explore Other Research Areas
Ready to Advance Your Research?
Every Nexora Pharma compound is batch-documented, with the Certificate of Analysis available on request. Tracked UK delivery. Temperature-controlled packaging as standard.